H6D0 Stock Chart & Stats
€4.33
-€0.01(-0.22%)
At close: 4:00 PM EDT
€4.33
-€0.01(-0.22%)
Day’s Range― - ―
52-Week Range€3.72 - €4.78
Previous CloseN/A
Volume16.56K
Average Volume (3M)18.33K
Market Cap
€34.95B
Enterprise Value€38.50K
Total Cash (Recent Filing)€826.00M
Total Debt (Recent Filing)€8.25B
Price to Earnings (P/E)18.7
Beta0.25
Next Earnings
Mar 04, 2027EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding8,796,549,000
10 Day Avg. Volume11,801
30 Day Avg. Volume18,330
Financial Highlights & Ratios
PEG Ratio1.05
Price to Book (P/B)2.05
Price to Sales (P/S)3.05
P/FCF Ratio16.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.80Price Target Upside10.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€132.64M
Bulls Say, Bears Say
Bulls Say
Durable Cash GenerationSustained operating and free cash flow gives Haleon internal funding for brand investment, innovation, debt reduction and shareholder returns, while reducing reliance on external financing across its consumer-health markets.
Margin Expansion And SavingsRecent margin gains and structural productivity programs can strengthen earnings durability by offsetting inflation and funding advertising, innovation and distribution investments without relying only on price increases.
Brand And Channel StrengthPerformance in oral care, supported by established brands and clinical innovation, plus faster digital growth, reinforces Haleon's competitive position and broadens consumer access across resilient self-care categories.
Bears Say
Elevated LeverageDebt reduction is positive, but leverage remains structurally higher than earlier periods and assets have declined since 2022, limiting financial flexibility if category weakness, inflation or execution pressures persist.
Respiratory Category WeaknessPersistent weakness in respiratory and cold-and-flu products creates a category-level drag on growth and leaves Haleon dependent on recovery timing, while competitors continue introducing new innovations.
Regional And Pricing PressureWeak regional demand and negative APAC pricing can constrain organic growth and margins over several quarters, especially where inflation, contract roll-offs and hospital-channel competition reduce realized prices.
Haleon PLC News
H6D0 FAQ
What was Haleon PLC’s price range in the past 12 months?
Haleon PLC lowest stock price was €3.71 and its highest was €4.78 in the past 12 months.
What is Haleon PLC’s market cap?
Haleon PLC’s market cap is €34.95B.
When is Haleon PLC’s upcoming earnings report date?
Haleon PLC’s upcoming earnings report date is Mar 04, 2027 which is in 168 days.
How were Haleon PLC’s earnings last quarter?
Haleon PLC released its earnings results on Jul 30, 2026. The company reported €0.05 earnings per share for the quarter, missing the consensus estimate of €0.057 by -€0.007.
Is Haleon PLC overvalued?
According to Wall Street analysts Haleon PLC’s price is currently Undervalued.
Does Haleon PLC pay dividends?
Haleon PLC does not currently pay dividends.
What is Haleon PLC’s EPS estimate?
Haleon PLC’s EPS estimate is 0.13.
How many shares outstanding does Haleon PLC have?
Haleon PLC has 8,796,549,000 shares outstanding.
What happened to Haleon PLC’s price movement after its last earnings report?
Haleon PLC reported an EPS of €0.05 in its last earnings report, missing expectations of €0.057. Following the earnings report the stock price went down -2.927%.
Which hedge fund is a major shareholder of Haleon PLC?
Currently, no hedge funds are holding shares in DE:H6D0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Haleon PLC Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.80 (10.87% Upside)
€4.80 (10.87% Upside)
Blogger Sentiment
Bullish
DE:H6D0 Sentiment 100%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth €548.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.05%
12-Months-Change
Fundamentals
Return on Equity
1.35%
Trailing 12-Months
Asset Growth
2.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Haleon PLC
Haleon plc operates as a global entity focused on developing, manufacturing, and marketing an array of consumer health products. Its operations extend across multiple continents, specifically North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers a comprehensive selection of items, encompassing therapeutic oral care, pain relief solutions, respiratory health aids, digestive wellness products, as well as vitamins, minerals, and other dietary supplements. Prominent brands within its extensive portfolio include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The firm, incorporated in 2021, was initially named DRVW 2022 plc before rebranding to Haleon plc in February 2022. Its corporate headquarters are located in Brentford, United Kingdom.
H6D0 Stock 12 Month Forecast
Average Price Target
€4.80
▲(10.87% Upside)
Technical Analysis
Allergy Therapeutics
―
Provexis
―
Shield Therapeutics
―
Venture Life
―
Beximco Pharmaceuticals Limited Sponsored GDR RegS
―